WO2004064788A2 - Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus - Google Patents
Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus Download PDFInfo
- Publication number
- WO2004064788A2 WO2004064788A2 PCT/US2004/000955 US2004000955W WO2004064788A2 WO 2004064788 A2 WO2004064788 A2 WO 2004064788A2 US 2004000955 W US2004000955 W US 2004000955W WO 2004064788 A2 WO2004064788 A2 WO 2004064788A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- peptide
- cyclodextrin
- hours
- concentration
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 113
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title description 56
- 238000009472 formulation Methods 0.000 title description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 80
- 230000008569 process Effects 0.000 claims abstract description 69
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 65
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 239000008365 aqueous carrier Substances 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 14
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 claims abstract description 11
- 229960004853 betadex Drugs 0.000 claims description 128
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 117
- 239000001116 FEMA 4028 Substances 0.000 claims description 59
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 49
- 159000000021 acetate salts Chemical group 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical group OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 16
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 claims description 10
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 claims description 10
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 claims description 10
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims description 10
- 108010055341 glutamyl-glutamic acid Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- VMSUVWZFCQSDRU-UHFFFAOYSA-N 3-(3-sulfopropoxy)propane-1-sulfonic acid Chemical group OS(=O)(=O)CCCOCCCS(O)(=O)=O VMSUVWZFCQSDRU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- QYPKJXSMLMREKF-BPUTZDHNSA-N Glu-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N QYPKJXSMLMREKF-BPUTZDHNSA-N 0.000 claims 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 claims 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 claims 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 1
- 108010077112 prolyl-proline Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 9
- ZEAYJGRKRUBDOB-GARJFASQSA-N Arg-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZEAYJGRKRUBDOB-GARJFASQSA-N 0.000 abstract 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 abstract 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 abstract 1
- ATEQEHCGZKBEMU-GQGQLFGLSA-N Ser-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N ATEQEHCGZKBEMU-GQGQLFGLSA-N 0.000 abstract 1
- 108010064235 lysylglycine Proteins 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 description 110
- 239000000243 solution Substances 0.000 description 55
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 229940068196 placebo Drugs 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 229940126534 drug product Drugs 0.000 description 13
- 239000000825 pharmaceutical preparation Substances 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000008137 solubility enhancer Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003172 anti-dna Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940113088 dimethylacetamide Drugs 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 238000012792 lyophilization process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000012395 formulation development Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000501458 Cultus Species 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000004368 gonadotroph Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940124625 intravenous corticosteroids Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000020402 negative regulation of interleukin-2 secretion Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- SLE Systemic lupus erythematosus
- lupus is a debilitating autoimmune disease characterized by the presence of an array of autoantibodies, including antibodies to dsDNA, to nuclear antigens and to ribonucleoproteins .
- SLE affects approximately 1 in 2000 individuals (U.S. 1 in 700 women). The disease primarily affects young women, with a female-to male ratio of approximately 9:1.
- Systemic lupus can affect almost any organ or system of the body. Systemic lupus may include periods in which few, if any, symptoms are evident (“remission”) and other times when the disease becomes more active (“flare”) . Most often when people mention "lupus,” they are referring to the systemic form, of the disease .
- Corticosteroids are the mainstay in treating systemic autoimmune disorders. Life threatening, severely disabling manifestations of SLE are treated with high doses of glucocorticoids (1-2 mg/kg/day) . Undesirable effects of chronic glucocorticoids include an array of prominent adverse effects such as cushingoid habitus, central obesity, hypertension, infection, capillary fragility, hirsutism, accelerated osteoporosis, cataracts, diabetes mellitus, yopathy and psychosis. In addition to corticosteroid toxicity, patient compliance to a dosage regimen also poses a serious problem.
- Cytotoxic agents are also used for controlling active disease, reducing the rate of disease flares, and reducing steroid requirements.
- Undesirable side effects of the latter include bone marrow depression, increased infections with opportunistic organisms, irreversible ovarian failure, alopecia and increased risk of malignancy.
- SLE is an inflammatory disease for which to date there is no definitive treatment or cure.
- the disease results in acute and chronic complications.
- the only treatments available are palliative, aimed at relieving acute symptoms and preventing chronic complications, often with profound side effects. There is therefore an unmet need in this field, and both physicians and patients would welcome new treatments which could potentially eliminate or reduce the unwanted manifestations of the disease.
- Peptides based on the complementarity-determining region of the human monoclonal anti-DNA 16/ ⁇ ld antibody capable of immunomodulating SLE associated responses have been disclosed in PCT International Publication Wo. WO 02/067848 A2 , the entire contents of which are hereby incorporated by reference.
- region CDRl was found to inhibit the proliferative response of peripheral blood lymphocytes (PBL) of SLE patients to the human anti-DNA 16/6ld AB, and to ameliorate disease manifestations of mice afflicted with spontaneous or experimental SLE.
- Human CDRl is a synthetic peptide of 19 amino acids based on the complementarity- determining region 1 (CDRl) of the human anti-dsDNA Ab denoted 16/6 Id (Waisman, A., et al . "Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti-DNA monoclonal antibodies.” Proc. Natl . Acad. Sci . U. S.A. (1997), 94(4): 4620- 4625) .
- CDRl complementarity- determining region 1
- the subject invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-cooH (SEQ ID NO:l) ;. and a substituted ⁇ -cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of an acetate salt of a peptide having the structural formula NH 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-cooH (SEQ ID NO:l) ; and from 70 mg/ml to 170 mg/ml of the composition of hepta- (sulfobutyl ether) - ⁇ -cyclodextrin, wherein the peptide and the hepta- (sulfobutyl ether) - ⁇ - cyclodextrin are dissolved in the aqueous carrier; and wherein the solution has a pH between 6.5 and 8.5.
- the subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SL-E) in a human subject comprising administering to the human subject any of the above pharmaceutical compositions in an amount effective to alleviate the symptoms of SLE in the human subject.
- the subject invention also provides a process for manufacturing the above pharmaceutical composition comprising the steps of:
- the subject invention also provides a process of lyophilizmg the above pharmaceutical composition, comprising the steps of: a) lowering the temperature of the pharmaceutical composition to -40°C; b) holding the temperature at -40°C for a predetermined time; c) raising the temperature of the solution to 20°C; d) holding the temperature at 20°C for a predetermined time; and e) reducing the pressure to lO ⁇ bar, thereby lyophilizmg the pharmaceutical composition.
- the subject invention also provides a process of lyophilizmg the above pharmaceutical composition, comprising the steps of: a) lowering the temperature of the pharmaceutical composition to -45°C; b) holding the temperature at -45°C for a predetermined time; c) raising the temperature of the solution to -20°C; d) raising the temperature of the solution to 25°C; and e) holding the temperature at 25°C for a predetermined time, thereby lyophilizmg the pharmaceutical composition.
- Figure 1 Human CDRl (Compound 1) as acetate salt - showing the molecular and structural formulas of hCDRl, the amino acid sequence, and physical parameters
- Kidney sections from (NZBxNZW) FI mice showing intensity of Immune Complex Deposits The top row sections are from a Captisol®-treated mouse, the mid-row sections are from a mouse treated with 50 ⁇ g/mouse Compound 1 and the bottom row sections are from a mouse treated with 25 ⁇ g/mouse Compound 1. Magnification : Left: xlOO, Right: x400. FITC immunohistology.
- the subject invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula H 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-cooH (SEQ ID N0:1) ; and a substituted ⁇ -cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9.
- the concentration of the acetate salt of the peptide is at least 0.5 mg/ml .
- the concentration of the salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 0.5 mg/ml to 2.5 mg/ml .
- the concentration of the salt of the peptide is from 2.5 mg/ml to 5 mg/ml .
- the concentration of the salt of the peptide is from 5 mg/ml to 7 mg/ml.
- the concentration of the salt of the peptide is from 7 mg/ml to 8.5 mg/ml.
- the concentration of the salt of the peptide is from 8.5 mg/ml to 10 mg/ml. In another embodiment, the concentration of the salt of the peptide is from 9 mg/ml to 10 mg/ml .
- the concentration of the salt of the peptide is from 10 mg/ml to 15 mg/ml.
- the concentration of the salt of the peptide is from 15 mg/ml to 20 mg/ml.
- the concentration of the salt of the peptide is 1.0 mg/ml.
- the concentration of the salt of the peptide is 2.5 mg/ml .
- the concentration of the salt of the peptide is 5 mg/ml.
- the concentration of the salt of the peptide is 10 mg/ml.
- the concentration of the salt of the peptide is 15 mg/ml.
- the concentration of the salt is from 0.1 mg/ml to 0.5 mg/ml .
- the concentration of the salt is from 0.1 mg/ml to 0.2 mg/ml.
- the concentration of the salt is from 0.2 mg/ml to 0.3 mg/ml . In another embodiment, the concentration of the salt is from 0.3 mg/ml to 0.4 mg/ml.
- the concentration of the salt is from 0.4 mg/ml to 0.5 mg/ml .
- the composition has a pH between 6.5 and 8.5.
- the composition has a pH between 7.5 and 8.5.
- the composition has a pH between 4 and 5.
- the composition has a pH between 5 and 6.
- the composition has a pH between 6 and 7.
- the composition has a pH between 7 and
- the composition has a pH between 8 and 9.
- the pharmaceutically acceptable salt is an acetate salt.
- the substituted ⁇ -cyclodextrin is a hydroxypropyl , a sulfobutyl ether, or a sulfopropyl ether substituted ⁇ -cyclodextrin.
- the substituted ⁇ -cyclodextrin is a sulfobutyl ether substituted ⁇ -cyclodextrin.
- the pharmaceutically acceptable salt is an acetate salt
- the substituted ⁇ -cyclodextrin is hepta- (sulfobutyl ether) - ⁇ -cyclodextrin.
- the composition further comprises a pharmaceutically acceptable buffer in an amount and of a type suitable to make the pH of the pharmaceutical composition in the range of 4-9.
- the buffer may be acetate buffer, citrate buffer, or sodium carbonate.
- the subject invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of an acetate salt of a peptide having the structural formula NH 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-cooH (SEQ ID NO:l) ; and from 70 mg/ml to 170 mg/ml of the composition of hepta- (sulfobutyl ether) - ⁇ -cyclodextrin, wherein the peptide and the hepta- (sulfobutyl ether) - ⁇ - cyclodextrin are dissolved in the aqueous carrier; and wherein the composition has a pH between 6.5 and 8.5.
- the concentration of the acetate salt of the peptide is at least 0.5 mg/ml .
- the concentration of the acetate salt of the peptide is from 0.5 mg/ml to 10 mg/ml.
- the concentration of the acetate salt of the peptide is from 0.5 mg/ml to 2.5 mg/ml. In another embodiment, the concentration of the salt is from 0.1 mg/ml to 0.5 mg/ml .
- the concentration of the salt is from 0.1 mg/ml to 0.2 mg/ml .
- the concentration of the salt is from 0.2 mg/ml to 0.3 mg/ml.
- the concentration of the salt is from 0.3 mg/ml to 0.4 mg/ml.
- the concentration of the salt is from 0.4 mg/ml to 0.5 mg/ml .
- the concentration of the salt of the peptide is from 5 mg/ml to 7 mg/ml .
- the concentration of the salt of the peptide is from 7 mg/ml to 8.5 mg/ml .
- the concentration of the salt of the peptide is from 8.5 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 9 mg/ml to 10 mg/ml.
- the concentration of the salt of the peptide is from 10 mg/ml to 15 mg/ml.
- the concentration of the salt of the peptide is from 15 mg/ml to 20 mg/ml. In a further embodiment, the concentration of acetate salt of the peptide is 1.0 mg/ml .
- the concentration of acetate salt of the peptide is 2.5 mg/ml .
- the concentration of the salt of the peptide is 5 mg/ml.
- the concentration of the salt of the peptide is 10 mg/ml.
- the concentration of the salt of the peptide is 15 mg/ml.
- the concentration of hepta- (sulfobutyl ether) - ⁇ -cyclodextrin is 120 mg/ml and the pH of the composition is between 7.5 and 8.5.
- the subject invention also provides a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject any of the above pharmaceutical compositions in an amount effective to alleviate the symptoms of SLE in the human subject.
- SLE systemic lupus erythematosus
- the subject invention also provides the above pharmaceutical compositions for use in treating SLE in a human subject.
- the subject invention also provides a process for manufacturing any of the above pharmaceutical compositions comprising the steps of: a) preparing a solution of a substituted ⁇ -cyclodextrin in an aqueous carrier at a predetermined concentration; b) adding predetermined amount of a pharmaceutically acceptable salt of the peptide NH 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-COOH (SEQ ID NO: 1) to the solution of step a) ; c) adjusting the pH of the solution of step b) until the peptide dissolves in the solution; and d) if necessary, adjusting the pH of the solution of step c) to a pH of 4-9, thereby manufacturing the pharmaceutical composition.
- the resulting final concentration of the substituted ⁇ -cyclodextrin in the pharmaceutical composition is from 70 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 80 mg/ml to 170 mg/ml.
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 90 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 100 mg/ml to 170 mg/ml . In one embodiment of the process, the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 110 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 120 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 130 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 140 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 150 mg/ml to 170 mg/ml .
- the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition of from 160 mg/ml to 170 mg/ml . In one embodiment of the process, the predetermined concentration of the substituted ⁇ -cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition is 120 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is at least 0.1 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is at least 0.5 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is 2.5 mg/ml, 2.0mg/ml, l.Omg/ml, 0.5 mg/ml or 0.1 mg/ml.
- the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is 5 mg/ml, 10 mg/ml or 15 mg/ml.
- step b) further comprises mixing the solution for l.hour.
- step c) the pH is adj sted using HCl or NaOH 1. ON.
- the process further comprises filtering the solution of step d) through a cellulose acetate filter.
- the predetermined concentration of the substituted ⁇ - cyclodextrin is such which results in a final concentration of substituted ⁇ -cyclodextrin in the pharmaceutical composition is 120 mg/ml; the predetermined amount of peptide is such which results in a final concentration of peptide in the pharmaceutical composition is 2.5 mg/ml, 2.0mg/ml,
- step b) further comprises mixing the solution for 1 hour; and in step c) the pH is adjusted using HC1 or aOH 1.0N, and the process further comprises filtering the solution of step d) through a cellulose acetate filter.
- the subject invention also provides a composition prepared by the above process.
- the subject invention also provides a process of lyophilizmg the above pharmaceutical composition, comprising the steps of: a) lowering the temperature of the pharmaceutical composition to -40°C; b) holding the temperature at -40°C for a predetermined time; c) raising the temperature of the solution to 20°C; d) holding the temperature at 20°C for a predetermined time; and e) holding the temperature at 25°C for a predetermined time, thereby lyophilizmg the pharmaceutical composition.
- step a) is performed within 2 hours .
- step b) is performed within 3 hours.
- step c) is performed over 13 hours. In a further embodiment, step c) is performed at a pressure of HO ⁇ bar.
- step d) is performed over 13 hours.
- step d) is performed at a pressure of llO ⁇ bar.
- step e) the pressure is reduced to lO ⁇ bar.
- step e) is performed over 5 hours.
- step a) is performed within 2 hours; step b) is performed within 3 hours; step c) is performed over 13 hours and at a pressure of llO ⁇ bar; step d) is performed over 13 hours and at a pressure of llO ⁇ bar; and step e) is performed over 5 hours and the pressure is reduced to lO ⁇ bar.
- the subject ' invention also provides a lyophilized pharmaceutical composition prepared by the above process .
- the subject invention also provides a process of lyophilizmg the above pharmaceutical composition, comprising the steps of: a) lowering the temperature of the pharmaceutical composition to -45°C; b) holding the temperature at -45°C for a predetermined time; c) raising the temperature of the solution to -20°C; d) raising the temperature of the solution to 25°C; and e) holding the temperature at 25°C for a predetermined time, thereby lyophilizmg the pharmaceutical composition.
- step a) is performed within 6 hours.
- step b) is performed within 3 hours.
- step c) is performed over 19 hours.
- step c) is performed at a pressure of 150 ⁇ bar .
- step d) is performed over 13 hours.
- step d) is performed at a pressure of 150 ⁇ bar .
- step e) is performed over 8 hours.
- step e) is performed at a pressure of 150 ⁇ bar .
- step a) is performed within 6 hours; step b) is performed within 3 hours; step c) is performed over 19 hours and at a pressure of ISO ⁇ bar; step d) is performed over 13 hours and at a pressure of ISO ⁇ bar; and step e) is performed over 8 hours and at a pressure of ISO ⁇ bar.
- the subject invention also provides a lyophilized pharmaceutical composition prepared by any of the above processes .
- the water content of the composition is less than 5%.
- the water content of the composition is less than 4.0%.
- the water content of the composition is less then 3.5%.
- the subject invention also provides a lyophilized pharmaceutical composition
- a lyophilized pharmaceutical composition comprising a pharmaceutically acceptable salt of a peptide having the structural formula NH 2 -Gly Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Pro Gly Lys Gly Glu Glu Trp He Gly-cooH (SEQ ID NO : 1 ) ; and a substituted ⁇ -cyclodextrin.
- the subject invention also provides a packaged pharmaceutical composition comprised of: a packaging material; and a predetermined amount of the above lyophilized pharmaceutical composition.
- the preparations of the present invention may be given parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered by injection, inhalation, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories .
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- the human hCDRl peptide (Compound 1) is described in PCT International Publication No WO 02/067848, published September 6, 2002, and can be prepared by methods well known in the art, (see, for example, Peptides: Synthesis, Structure and Applications, ed. by B. Gutte, Academic Press, 1995; Peptide Synthesis Protocols, ed. By M. Pennington and B. Dunn, Humana Press, 1994; Schnolzer, M. et al . , "In situ neutralization in Boc-chemistry solid phase synthesis. Rapid, High yield assembly of difficult sequences.” Int . J. Pept . Protein Res . (1992) 40: 180-193) .
- Compound 1 is a synthetic polypeptide composed of 19 amino acids . It is provided as an acetate salt . The aqueous solubility of the peptide has been determined to be less than
- Figure 1 shows compound 1 as an acetate salt .
- Compound 1 was dissolved in the chosen solubility enhancer solution either separately or in combination with other excipients and the solutions were stirred for at least an hour. The pH was adjusted if needed. The solutions were visually examined to estimate the solubility and sent for analytical assay determination. For a few chosen formulations, biological activity was also tested.
- Table 1 presents the type of solubility enhancers used for the formulation development.
- Tables 2 and 3 summarize the experiments that were performed with the various solubility enhancers .
- Table 2 summarizes the initial screening performed with peptide concentrations in the range of 5 to 10 mg/ml. The experimental work that was performed with higher peptide concentration was then repeated with the lower doses (see table 3)
- Non aqueous solvents such as Ethanol, Glycerin, Propylene glycol, Chremophore and their combinations were tested but did not increase the solubility of Compound 1.
- a solution of 30% DMA (dimethyl-acetamide) yielded solubility in the desired ranges (5 to 9 mg/ml) , but was not suitable for a pharmaceutical formulation due to its toxicity profile. Improved solubility was also observed using 30% (w/w) PEG 400 (5 to 9 mg/ml) .
- This latter formulation was chosen for the toxicology studies, but it has proved to be both inactive in the biological assay, and may have been the cause of some adverse effects in a mouse toxicity study. Thus, it was decided not to further pursue this formulation. In view of the preliminary experiments non-aqueous solvents were not used in the subject formulations.
- cyclodextrins Two types of cyclodextrins, both approved for use in marketed parenteral products, were also tested: Hydroxypropyl- ⁇ - cyclodextrin and Sulfobutylether- ⁇ -cyclodextrin (Captisol®) . Both markedly increased the solubility of the peptide (concentrations in the levels of 10 mg/ml for Hydroxypropyl- ⁇ - cyclodextrin and 2.5 for Captisol®). The biological activity of the two cyclodextrin formulations was tested and was found to be equal to the activity of the peptide alone.
- CAPTISOL® is a commercially available polyanionic ⁇ - cyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl ether spacer group, or sulfobutylether (SBE) .
- CAPTISOL® is the trade name for CyDex
- CAPTISOL® s hepta-substituted sulfobutylether ⁇ -cyclodextrin (SBE7- ⁇ -CD) preparation (www.captisol.com).
- SBE7- ⁇ -CD s hepta-substituted sulfobutylether ⁇ -cyclodextrin
- the structure of CAPTISOL® allows drug molecules to fit in the hydrophobic cavity, thereby isolating the drug molecule from the aqueous solvent. Because the outer surface of CAPTISOL® is hydrophilic, the solubility of the complexed drug- molecule is thereby enhanced.
- the use of cyclodextrins to enhance the solubility of drug molecules is disclosed in U.S. Patent Nos. 5,134,127 and
- CAPTISOL® is safe when administered parenterally and does not exhibit the nephrotoxicity associated with beta-cyclodextrin. Relative to beta-cyclodextrin, CAPTISOL® provides comparable or higher complexation characteristics and superior water solubility in excess of 90 grams/lOOml - a 50-fold improvement.
- solubility enhancers were found to match the desired solubility range: DMA, PEG-400, dimethyl-acetamide, polyethylene glycol, polyoxylated castor oil, N-methyl-2- pyrrolidinone, l-ethenyl-2-pyrrolidinone, Polysorbate 20,
- Captisol® Sulfobutylether- ⁇ -cycldextrin
- solubility enhancers both cyclodextrins have proven to be superior with respect to solubility, biological activity and stability.
- Captisol® As the solubility enhancer for use in Example 5 formulations and to further study both cyclodextrin formulations .
- the final formulation for the Example 5 clinical studies consists of: 120 mg/ml of Captisol® in water with the desired amount of peptide (0.5, 1.0 or 2.5 mg/ml), and HCl and NaOH for pH adjustment.
- Standard dissolution methods such as mixing dry Compound 1 and dry Captisol® into water or adding Compound 1 to a prepared solution of Captisol® and water did not result in complete dissolution at the desired concentrations.
- concentrations of both Compound 1 and Captisol® were tested at various pH levels. However, the following method for producing a solution of Compound 1 in Captisol® resulted in complete dissolution at the desired concentrations.
- the current lyophilization process differs from other lyophilization processes in that the percentage of solids in the formulation is high (12%) whereas lyophilized products normally contain between 5 and 10% solids.
- the freeze drier used was an Edwards lyophilizer Lyoflex 0.6.
- the equipment IQ/OQ was performed and checked for compliance by quality assurance prior to the process development.
- Freezing - Freezing was from room temperature to -40°C within 2 hours. Shelves were held at -40°C for 3 hours.
- Drying - Drying was performed at 110 ⁇ bar pressure. Shelf temperature was increased to 20°C over 13 hours and held at that temperature for additional 13 hours .
- the biological activity was monitored by inhibition of IL-2 secretion from Compound 1 reference standard (RS) specific T- cells following subcutaneous (s.c.) treatment with the lyophilized compound solution, i.e. the drug product (DP), at two concentrations .
- the results of the treatment are compared to those of treating mice with Compound 1 (RS) in phosphate buffered saline (PBS) . The results are shown in the tables below and in Figure 2.
- Activator 50 200 activator ( ⁇ g/ml) Ampulized 50 inhib. 200 inhib. inhib. inhib. ⁇ g/mouse ⁇ g/mouse ⁇ g/mouse ⁇ g/mouse
- mice were immunized with 50 ⁇ g/mouse of Compound 1 RS .
- the immunized mice were allocated to five treatment groups as follows: placebo, 25, 50, 100 and 200 ⁇ g/mouse of Compound 1 DP (subcutaneous administration) .
- mice 20 female BALB/c mice, supplied by Harlan animals breeding center, Rehovot.
- CFA-Compound 1 RS emulsion 500 ⁇ g/ l, 50 ⁇ g/mouse was prepared as follows :
- Treatment was by a s.c. injection of 200 ⁇ l solution.
- captisol® 1.2 gr were dissolved in 10 ml of WFI to yield a solution of 12% captisol®.
- mice were weighed before immunization. Average mice weight: 19.01 ⁇ 0.97 gr ⁇ stsffiuni ⁇ s, a t i on
- the immunization was performed by injecting 100 microliters of the emulsion (50 microliters into each hind footpad) .
- mice were treated by s.c. injection of 200 ⁇ l from the designated Compound 1 DP or 12% captisol® treatment solutions, at the back of their neck.
- In-vitro culture 200 ⁇ l from the designated Compound 1 DP or 12% captisol® treatment solutions, at the back of their neck.
- mice were sacrificed by cervical dislocation. LN were extracted from the hind legs and were transferred to a sterile petri dish containing about 5 mL RPMI. The cells were extracted by gentle squeezing of the tissue against a 200 micrometer mesh stainless steel net. The cells were collected and centrifuged at 300 G for 10 minutes at RT.
- the 10 x 10 6 cells/ml suspensions were diluted 1:2 by adding 5 ml EM-1 to 5 ml cells suspension.
- tissue culture plates were prepared. The following was added to each plate .
- ystem positive control (cells stimulated with Con S ) 0.5 ml of cells suspension 0.5 ml of Con A 5 ⁇ g/ml in EM-1 (final cone. 2.5 ⁇ g/well)
- 96-wells plates were prepared by applying 100 ⁇ l from the cell suspension and 100 ⁇ l from the activation solutions .
- the culture plates were incubated at 37° C in a humidified 5% C0 2 incubator, for either 48 or 72 hrs .
- the cultured plates were centrifuged at 300 g for 10 minutes at RT. Supernatants (850 ⁇ l from each well) were transferred either to mirror plates or to tubes . The supernatant was then divided into working aliquots (two aliquots of 200 and one aliquot of 450 ⁇ l) , in order to avoid repeated freeze/thawing of the samples . Each tube was labeled with the following details :
- TGF- ⁇ secretion 1 In the placebo group, no dose response upon in vitro activation with compound 1 was seen. TGF- ⁇ secreted level was below the detection limit of the ELISA in all other treatment groups .
- Example 6 Optimizations of freeze drying cycle with Compound 1 and Captisol® for injection (0, 0.5, 1.0 and 2.5 mg/vial)
- Example 7 Effect of Compound 1 (administered in Captisol®) on lupus symptoms in the SLE-prone (NZBxNZ )Fl female mouse
- Captisol ® sulfobutyl ether beta-cyclodextrin sodium
- mice were followed for anti-dsDNA antibodies and for proteinuria. When the mice were sacrificed, the intensity of ICD was determined in kidneys .
- Table 13 also shows that the beneficial effect of treatment with Compound 1 could be observed starting from the 5 th injection and it was sustained up to the 10 th injection.
- the mean levels of proteinuria in the Captisol ® control group were consistently higher than in the Compound 1 -treated groups.
- Table 13 also shows that a reduction in the intensity of ICD was observed in kidneys of both Compound 1 dose groups . There was an overall trend showing that the lower dose (25 ⁇ g/mouse) was more effective than the higher dose (50 ⁇ g/mouse) in reducing the clinical -symptoms of SLE in these mice.
- Figure 6 shows representative sections of one kidney from each treatment group.
- the top row sections are from a Captisol ® - treated mouse
- the mid-row sections are from a mouse treated with 50 ⁇ g/mouse Compound 1
- the bottom row sections are from a mouse treated with 25 ⁇ g/mouse Compound 1. It can be seen that the intensity of immune complex deposits observed in kidney sections of mice treated with Compound 1 (dissolved in Captisol ® ) at either dose level was much lower than that observed in the control group .
- SLE patients Thirty-six (36) subjects participated in the study. To be eligible for inclusion in the study, SLE patients must have fulfilled at least four criteria used for . the diagnosis of lupus by the American College of Rheumatology. Patients must also have had stable, mild/moderate disease and score less than or equal to 10 on the SLE Disease Activity Index, SLEDAI .
- Anti-ENA including anti-La, anti-Ro, anti-RNP, anti- Sm
- Anti-cardiolipin antibodies a VDRL ⁇ FTA antibodies
- Vials of Compound 1 in Captisol ® 120mg/vial were injected subcutaneously as a single dose per subject in the following dosages :
- Placebo for Compound 1 120 mg Captisol ⁇ /vial (identical in appearance to vials of Compound 1 in Captisol ® ) . This was a multi-center, randomized; double blind, placebo- controlled, four-arm study, using a single subcutaneous injection of Compound 1 or placebo. SLE patients were screened up to 21 days prior to baseline procedures. Each eligible subject was randomized to one of the 4 treatment groups: subcutaneous injection of either 0.5, 1 or 2.5 mg Compound 1 or its matching placebo. All subjects were admitted to the clinic on pre-dosing day. Each subject received a single dose of one of the above listed treatments. Subjects were discharged from the clinic 24 hours after dosing. Subjects were further monitored at weeks 2, 4 and 8 following dosing.
- Blood samples serum and whole blood for safety laboratory tests were withdrawn at Screening, Dosing Day (pre-dose) , Day 2 (post dose), at Weeks 2, 4 and 8 (Termination visit) .
- Blood samples for immunological tests were withdrawn at: Screening, Dosing Day (pre-dose) and at Weeks 4 and 8.
- Peripheral blood lymphocytes (PBL) proliferation was evaluated at Dosing Day (pre-dose) and at Weeks 2, 4 and 8.
- SLE disease activity index year 2000 updated (SLEDAI 2K) .
- SLE patients who reported unstable or severe asthma, stroke, acute myocardial infarction, unstable angina, cerebral hemorrhage and pulmonary embolism during the six months prior to study screening.
- SLE patients who had any clinically significant or unstable medical or surgical conditions, diabetes mellitus, liver disease (cirrhosis, active hepatitis, portal hypertension, and/or ascites) , clinically significant hypertension, a medical history of any malignancy, dialysis, or chronic obstructive pulmonary disease (COPD) were also excluded from study participation.
- COPD chronic obstructive pulmonary disease
- prednisone 30mg/day or greater or an equivalent dose of another corticosteroid
- corticosteroids or an equivalent dose of another corticosteroid
- IgG intravenous immunoglobulin G
- oral anticoagulants e.g. azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, methothrexate, tacrolimus.
- cytotoxic agents e.g. azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, methothrexate, tacrolimus.
- corticosteroids more than ⁇ 10 mg/day prednisone, or an equivalent dose of another corticosteroid
- anti- malarials during the last 3 months prior to screening were excluded from the study.
- Drug-related immunological responses were followed by using the PBL proliferation assay and anti-Compound 1 antibodies assay at the Dosing Day and at follow-up visits including Termination visit .
- Descriptive statistics for vital signs including number of observations, mean, standard deviation, median, minimum and maximum values were determined for Screening, Day 1 (pre and post dose, and at each time point) Day 2, Weeks 2, 4 and 8 are tabulated by the assigned treatment. Changes from baseline to each time point/visit is presented in by visit and treatment assignment.
- Descriptive statistics including mean, standard deviation, median, minimum and maximum values of SLEDAI 2K are presented.
- the peripheral blood lymphocytes (PBL) assay showed that 50 % of the subjects (18) were classified as responders (SI>2) with similar distribution in all treatment groups.
- the T cell response was relatively low and no association between Compound 1 treatment dose or concentration used in the assay and responder/ non-responder status could be detected, taking into consideration that only a single SC dose of the study drug was administered. Also, no indication of increased incidence of responder status over time was observed.
- the tetanus toxoid (TTX) assay that serves as a safety control shows that the response to TTX was preserved throughout the study period in all treatment groups indicating that Compound 1 in captisol® did not change the immunological response to TTX recall antigen.
- the immunological findings are the result of the administration of only a single dose of the study drug Compound 1.
- This study is being performed in order to evaluate the safety and tolerability of repeated Compound 1 sc administration to SLE subjects.
- the study's secondary objective is to evaluate immunological responses following repeated sc administration of Compound 1 in Captisol® in SLE subjects.
- Compound 1 is given in doses of 0.5, 1.0 or 2.5 mg in Captisol ® .
- the investigational product is administered every other day (excluding weekends) for a total of 12 sc injections, i.e. 3 doses a week for 4 weeks.
- Subjects are monitored on planned visits scheduled at 2, 4, 8 and 12 weeks after start of dosing. Safety and tolerability are evaluated using tests similar to those described in the Phase la Clinical Study above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05007552A MXPA05007552A (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus. |
AU2004206844A AU2004206844A1 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
JP2006500958A JP2006516034A (en) | 2003-01-14 | 2004-01-14 | Parenteral formulation of peptides for the treatment of systemic lupus erythematosus |
BR0406737-1A BRPI0406737A (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosis |
NZ541659A NZ541659A (en) | 2003-01-14 | 2004-01-14 | Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin |
EA200501129A EA008438B1 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erhythematosus |
UAA200507998A UA83816C2 (en) | 2003-01-14 | 2004-01-14 | Pharmaceutical composition comprising a peptide and substituted -cyclodextrin for the treatment of systemic lupus erythematosus |
CA002513331A CA2513331A1 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
EP04702214A EP1587525A4 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
IS7971A IS7971A (en) | 2004-01-14 | 2005-08-05 | Pharmaceutical preparation with peptide for parenteral treatment of diffuse cave erythema |
NO20053761A NO20053761L (en) | 2003-01-14 | 2005-08-08 | Parenteral peptide formulations for the treatment of systemic lupus erythematosus. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43995003P | 2003-01-14 | 2003-01-14 | |
US60/439,950 | 2003-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004064788A2 true WO2004064788A2 (en) | 2004-08-05 |
WO2004064788A3 WO2004064788A3 (en) | 2005-03-24 |
Family
ID=32771763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/000955 WO2004064788A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
Country Status (18)
Country | Link |
---|---|
US (2) | US7294687B2 (en) |
EP (1) | EP1587525A4 (en) |
JP (1) | JP2006516034A (en) |
KR (1) | KR20050100616A (en) |
CN (1) | CN1761477A (en) |
AU (1) | AU2004206844A1 (en) |
BR (1) | BRPI0406737A (en) |
CA (1) | CA2513331A1 (en) |
CO (1) | CO5640149A2 (en) |
CR (1) | CR7936A (en) |
EA (1) | EA008438B1 (en) |
EC (1) | ECSP055960A (en) |
MX (1) | MXPA05007552A (en) |
NO (1) | NO20053761L (en) |
NZ (1) | NZ541659A (en) |
UA (1) | UA83816C2 (en) |
WO (1) | WO2004064788A2 (en) |
ZA (1) | ZA200506205B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006027116A2 (en) * | 2004-09-10 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | P277 peptide formulations or variants thereof having optimised stability |
US7858738B2 (en) | 2001-02-26 | 2010-12-28 | Yeda Research And Development Co., Ltd. | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
US8865868B2 (en) | 2008-08-06 | 2014-10-21 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy |
US10633462B2 (en) | 2012-02-15 | 2020-04-28 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
US10780177B2 (en) | 2008-04-28 | 2020-09-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US10800861B2 (en) | 2012-10-22 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
US11795241B2 (en) | 2014-08-22 | 2023-10-24 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1594434T3 (en) * | 2003-01-14 | 2017-01-02 | Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science | Parenteral formulations of peptide for the treatment of systemic lupus erythematosus |
EA008438B1 (en) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Parenteral formulations of a peptide for the treatment of systemic lupus erhythematosus |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
WO2008073448A2 (en) * | 2006-12-12 | 2008-06-19 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations and methods for making the same |
MX2009007596A (en) * | 2007-01-16 | 2009-08-13 | Bipar Sciences Inc | Formulations for cancer treatment. |
AU2018205885A1 (en) | 2017-01-05 | 2019-06-27 | Yeda Research And Development Co. Ltd. | Peptides for treating Sjogren's syndrome |
CN110960442B (en) * | 2019-12-17 | 2023-03-31 | 珠海冀百康生物科技有限公司 | Preparation method of polypeptide encapsulate |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60184098A (en) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | Novel peptide and diuretic comprising it as active ingredient |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
KR0166088B1 (en) * | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
IL113159A0 (en) | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
US6613536B1 (en) | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
US20020054872A1 (en) | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
IL120503A0 (en) | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
JP4524039B2 (en) | 1997-12-18 | 2010-08-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Pyridone as an SRC family SH2 domain inhibitor |
IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
US7114005B2 (en) | 2002-02-05 | 2006-09-26 | Cisco Technology, Inc. | Address hopping of packet-based communications |
EA008438B1 (en) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Parenteral formulations of a peptide for the treatment of systemic lupus erhythematosus |
DK1594434T3 (en) * | 2003-01-14 | 2017-01-02 | Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science | Parenteral formulations of peptide for the treatment of systemic lupus erythematosus |
-
2004
- 2004-01-14 EA EA200501129A patent/EA008438B1/en not_active IP Right Cessation
- 2004-01-14 NZ NZ541659A patent/NZ541659A/en unknown
- 2004-01-14 EP EP04702214A patent/EP1587525A4/en not_active Withdrawn
- 2004-01-14 WO PCT/US2004/000955 patent/WO2004064788A2/en not_active Application Discontinuation
- 2004-01-14 UA UAA200507998A patent/UA83816C2/en unknown
- 2004-01-14 MX MXPA05007552A patent/MXPA05007552A/en active IP Right Grant
- 2004-01-14 BR BR0406737-1A patent/BRPI0406737A/en not_active IP Right Cessation
- 2004-01-14 CA CA002513331A patent/CA2513331A1/en not_active Abandoned
- 2004-01-14 AU AU2004206844A patent/AU2004206844A1/en not_active Abandoned
- 2004-01-14 US US10/758,572 patent/US7294687B2/en not_active Expired - Lifetime
- 2004-01-14 KR KR1020057013097A patent/KR20050100616A/en not_active Application Discontinuation
- 2004-01-14 CN CNA2004800069919A patent/CN1761477A/en active Pending
- 2004-01-14 JP JP2006500958A patent/JP2006516034A/en not_active Withdrawn
-
2005
- 2005-08-03 ZA ZA200506205A patent/ZA200506205B/en unknown
- 2005-08-08 NO NO20053761A patent/NO20053761L/en not_active Application Discontinuation
- 2005-08-09 CR CR7936A patent/CR7936A/en unknown
- 2005-08-10 CO CO05079319A patent/CO5640149A2/en not_active Application Discontinuation
- 2005-08-11 EC EC2005005960A patent/ECSP055960A/en unknown
-
2007
- 2007-11-12 US US11/985,068 patent/US20080287366A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1587525A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858738B2 (en) | 2001-02-26 | 2010-12-28 | Yeda Research And Development Co., Ltd. | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
WO2006027116A2 (en) * | 2004-09-10 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | P277 peptide formulations or variants thereof having optimised stability |
WO2006027116A3 (en) * | 2004-09-10 | 2007-01-25 | Sanofi Aventis Deutschland | P277 peptide formulations or variants thereof having optimised stability |
US10780177B2 (en) | 2008-04-28 | 2020-09-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US11806402B2 (en) | 2008-04-28 | 2023-11-07 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US8865868B2 (en) | 2008-08-06 | 2014-10-21 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy |
US10633462B2 (en) | 2012-02-15 | 2020-04-28 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
US11208500B2 (en) | 2012-02-15 | 2021-12-28 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
US10800861B2 (en) | 2012-10-22 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
US11795241B2 (en) | 2014-08-22 | 2023-10-24 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
Also Published As
Publication number | Publication date |
---|---|
BRPI0406737A (en) | 2005-12-20 |
US7294687B2 (en) | 2007-11-13 |
EP1587525A2 (en) | 2005-10-26 |
JP2006516034A (en) | 2006-06-15 |
CN1761477A (en) | 2006-04-19 |
MXPA05007552A (en) | 2006-05-19 |
EA200501129A1 (en) | 2006-02-24 |
US20040180059A1 (en) | 2004-09-16 |
CA2513331A1 (en) | 2004-08-05 |
NO20053761D0 (en) | 2005-08-08 |
ECSP055960A (en) | 2006-04-19 |
UA83816C2 (en) | 2008-08-26 |
US20080287366A1 (en) | 2008-11-20 |
CO5640149A2 (en) | 2006-05-31 |
NO20053761L (en) | 2005-10-12 |
ZA200506205B (en) | 2006-12-27 |
EA008438B1 (en) | 2007-06-29 |
AU2004206844A1 (en) | 2004-08-05 |
EP1587525A4 (en) | 2008-09-10 |
NZ541659A (en) | 2007-05-31 |
CR7936A (en) | 2006-05-31 |
KR20050100616A (en) | 2005-10-19 |
WO2004064788A3 (en) | 2005-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080287366A1 (en) | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus | |
AU620926B2 (en) | Cyclodextrin-peptide complexes | |
Conceicao et al. | Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art | |
US20090169559A1 (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus | |
US8785415B2 (en) | Oral formulations of cladribine | |
FI118537B (en) | Procedure for increasing cyclodextrin complexation | |
DE68906027T2 (en) | CYCLODEXTRIMPEPTIDE INCLUDING COMPLEXES. | |
EP2272503B1 (en) | Oral formulations of cladribine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 169573 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/007552 Country of ref document: MX Ref document number: 390.05 Country of ref document: BZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2513331 Country of ref document: CA Ref document number: 2006500958 Country of ref document: JP Ref document number: 1020057013097 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/06205 Country of ref document: ZA Ref document number: 200506205 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3481/DELNP/2005 Country of ref document: IN Ref document number: 2004206844 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 541659 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05079319 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004702214 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200501129 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2004206844 Country of ref document: AU Date of ref document: 20040114 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004206844 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048069919 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057013097 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004702214 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0406737 Country of ref document: BR |
|
WWR | Wipo information: refused in national office |
Ref document number: 390.05 Country of ref document: BZ |